Therapy of deep fungal infection in haematological malignancy. Working Party of the British Society for Antimicrobial Chemotherapy
A. G. Prentice(University of Birmingham), Richard Warren, J. Cohen(Centre de Nanosciences et de Nanotechnologies), R. J. Hay(Guy's Hospital), Thomas R. Rogers(Scripps Research Institute), David W. Denning(Manchester Academic Health Science Centre), E. G. V. Evans(St. Thomas Hospital), Rosemary A. Barnes(Cardiff University), D. C. E. Speller(National Public Health Laboratory), David W. Warnock(University of Alabama at Birmingham)
Cited by 23
Related Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision
|Journal of Fungi|2017|2.9k
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2016|2.8k
Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America
|Clinical Infectious Diseases|2008|2.7k